HELIOS: Back-to-back Endoscopy Versus Single-pass Endoscopy and Chromoendoscopy in IBD Surveillance

Sponsor
Radboud University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04291976
Collaborator
UMC Utrecht (Other), Leiden University Medical Center (Other), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Other)
560
4
3
23.6
140
5.9

Study Details

Study Description

Brief Summary

The current international guidelines for CRC surveillance in IBD recommend as first choice the use of chromoendoscopy, and as an alternative high-definition white light endoscopy (HDWLE) for optimal dysplasia detection, based on data from clinical trials. However, data on the superiority of CE over HDWLE are not consistent in literature. The investigators hypothesize that the better performance of CE in some clinical trials is the result of the associated longer procedural time and the fact that every colon segment is examined twice. Currently, no studies have been published evaluating the dysplastic yield of back-to back HDWLE compared to HDWLE with a single pass or CE in patients with IBD. In the present study, the investigators aim to compare the yield of dysplasia/CRC between 1) regular HDWLE, 2) HDWLE back-to-back, and 3) CE.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Back-to-back high-definition white light endoscopy
  • Procedure: single-pass high-definition white light endoscopy
  • Procedure: chromoendoscopy
N/A

Detailed Description

The investigators assume based on previous research a yield of 12% using high-definition white light endoscopy and 24% using either chromoendoscopy or high-definition white light endoscopy with a second examination (Imperatore et al 2019). To show non-inferiority of back-to-back HDWLE compared to CE, with a non-inferiority margin of 10% (power 80% and alpha 5%,) a total of 226 patients per group is required.

To demonstrate a superiority of back-to-back HDWLE compared to a regular HDWLE, with a 1:2 allocation ratio of single-pass vs back-to-back , 113 and 226 patients per group are needed to achieve 80% power with an alpha of 5%. Therefore, the investigators will include 226 patients in group back-to-back HDWLE, 226 in group CE, and 113 patients in group regular HDWLE. This amounts to a total of 560 patients. To account for any screen-failures The investigators will include at most 5% (of 560) additional patients until 80% power is reached.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
560 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a multicenter, non-blinded randomized trial with three parallel arms: back-to-back HDWLE, single-pass HDWLE and CE.This is a multicenter, non-blinded randomized trial with three parallel arms: back-to-back HDWLE, single-pass HDWLE and CE.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Back-to-back High-definition White Light Endoscopy Versus Single-pass High-definition White Light Endoscopy and Chromoendoscopy in IBD Surveillance
Actual Study Start Date :
Mar 13, 2020
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Mar 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: back-to-back HDWLE

Similar to single-pass HDWLE, with a second segmental inspection after the first examination in the same session. Equipment is similar to 1.

Procedure: Back-to-back high-definition white light endoscopy
Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached, with a second segmental inspection after the first examination in the same session.The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.

Active Comparator: single-pass HDWLE

Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.

Procedure: single-pass high-definition white light endoscopy
Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.

Active Comparator: Chromoendoscopy

After introduction of the endoscope into the colon a dye (methylene blue or 0.3% indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two arms.

Procedure: chromoendoscopy
After introduction of the endoscope into the colon a dye (methylene blue or indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two interventions.

Outcome Measures

Primary Outcome Measures

  1. detection rate of neoplasia for each technique [During endoscopy]

Secondary Outcome Measures

  1. Number of all lesions for each technique [During endoscopy]

  2. Number of dysplastic lesions for each technique [After each endoscopy, within one month after the procedure.]

  3. Kudo classification for each lesion [During endoscopy when a lesion is detected]

  4. Duration [During endoscopy]

    Total endoscopic procedure time and endoscopic procedure time during withdrawal for each technique.

  5. Number of targeted biopsies taken in the different groups. [During endoscopy]

  6. Percentage of non-interpretable/assessable endoscopies [During endoscopy]

    e.g. insufficient preparation, inflammation

  7. Location of the lesion [During endoscopy]

  8. Size of the lesion in mm [During endoscopy]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Signed informed consent

  • Patients with inflammatory bowel disease, an estimated involvement of at least 30% of the colonic surface and a disease duration of at least 8 years (or any disease duration in case of concomitant primary sclerosing cholangitis).

  • Previous assessable surveillance endoscopy > 1 year

  • Age > 18 years

Exclusion Criteria:
  • Active colitis > 20 cm and/or inflammation resulting in an insufficient surveillance procedure according to the endoscopist.

  • Allergy or intolerance to methylene blue

  • Insufficient bowel cleansing (BBPS <6)

  • Refusing or incapable to agree with informed consent

  • Pregnant women

  • 50 % of the colon surgically removed

Contacts and Locations

Locations

Site City State Country Postal Code
1 Radboudumc Nijmegen Gelderland Netherlands 6525GA
2 Utrecht University Medical Center Utrecht Gelderland Netherlands 3584CX
3 Amsterdam UMC, location AMC Amsterdam Noord-Holland Netherlands 1105 AZ
4 Leiden University Medical Center Leiden Zuid Holland Netherlands

Sponsors and Collaborators

  • Radboud University Medical Center
  • UMC Utrecht
  • Leiden University Medical Center
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Investigators

  • Principal Investigator: Frank Hoentjen, MD PhD, Radboud University Medical Center
  • Principal Investigator: Bas Oldenburg, MD PhD, UMC Utrecht

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Radboud University Medical Center
ClinicalTrials.gov Identifier:
NCT04291976
Other Study ID Numbers:
  • 109344
First Posted:
Mar 2, 2020
Last Update Posted:
Jul 23, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Radboud University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 23, 2021